Table 3.
Baseline predictors of final visual outcome after 12 months after surgery
| Baseline Measure | BCVA Loss >1 Line n (%) | BCVA Gain or Loss ≤1 Line n (%) | BCVA Gain >1 Line n (%) | P-value | OR (95% CI)* |
|---|---|---|---|---|---|
| Baseline BCVA(logMAR±SD)† | 0.45±0.06 | 0.43±0.17 | 0.67±0.38 | 0.248 | 1.120 (0.924-1.357) |
| Age group (years) | |||||
| 45-60 | 0/9 (0) | 1/9 (11) | 8/9 (89) | ||
| 61-75 | 2/26 (8) | 9/26 (34) | 15/26 (58) | 0.001 | 1.292 (1.109-1.505) |
| 76-90 | 2/15 (13) | 6/15 (40) | 7/15 (47) | <0.001 | 1.493 (1.228-1.814) |
| Lens status | |||||
| Phakic | 4/32 (13) | 10/32 (31) | 18/32 (56) | ||
| Pseudophakic | 0/18 (0) | 6/18 (33) | 12/18 (67) | 0.350 | 1.055 (0.943-1.180) |
| iERM Stage | |||||
| Stage 2 | 3/13 (23) | 2/13 (15) | 8/13 (62) | ||
| Stage 3 | 1/32 (3) | 13/32 (41) | 18/32 (56) | 0.046 | 0.848 (0.721-0.997) |
| Stage 4 | 0/5 (0) | 1/5 (20) | 4/5 (80) | 0.277 | 0.887 (0.715-1.101) |
| Macular edema | |||||
| MME | 2/20 (10) | 7/20 (35) | 11/20 (55) | ||
| CME | 1/15 (7) | 7/15 (47) | 7/15 (46) | 0.611 | 1.036 (0.903-1.188) |
| Combined ME | 1/15 (7) | 2/15 (13) | 12/15 (80) | 0.940 | 0.993 (0.833-1.185) |
| SRF | |||||
| Absence SRF | 4/42 (10) | 13/42 (31) | 25/42 (59) | ||
| Presence SRF | 0/8 (0) | 3/8 (38) | 5/8 (62) | 0.450 | 1.042 (0.936-1.160) |
| CBA | |||||
| Absence | 3/45 (7) | 15/45 (33) | 27/45 (60) | ||
| Presence | 1/5 (20) | 1/5 (20) | 3/5 (60) | 0.582 | 1.065 (0.852-1.330) |
| EZ continuity | |||||
| Continuous | 1/14 (7) | 4/14 (29) | 9/14 (64) | ||
| Disrupted | 3/36 (8) | 12/36 (33) | 21/36 (59) | 0.751 | 1.022 (0.893-1.169) |
| EIFL | |||||
| ≤100 | 3/23 (13) | 4/23 (17) | 16/23 (70) | ||
| >100µm | 1/27 (4) | 12/27 (44) | 14/27 (52) | <0.001 | 1.305 (1.127-1.512) |
| ONL | |||||
| ≤200 µm | 1/20 (5) | 9/20 (45) | 10/20 (50) | ||
| >200µm | 3/30 (10) | 7/30 (23) | 20/30 (67) | 0.071 | 1.139 (0.989-1.312) |
| CRT | |||||
| ≤450 µm | 3/20 (15) | 7/20 (35) | 10/20 (50) | 0.048 | 1.164 (1.001-1.353) |
| >450 µm | 1/30 (3) | 9/30 (30) | 20/30 (67) | ||
| Treatment | |||||
| Eye drops | 0/17 (0) | 7/17 (41) | 10/17 (59) | ||
| + parabulbous | 0/11 (0) | 8/11 (73) | 3/11 (27) | 0.073 | 1.154 (0.987-1.349) |
| + intravitreal | 4/22 (18) | 1/22 (5) | 17/22 (77) | 0.007 | 1.230 (1.059-1.427) |
BCVA: best corrected visual acuity, CI: confidence interval, iERM: idiopathic epiretinal membrane, CRT: central foveal thickness, ONL: outer nuclear layer thickness, EIFL: ectopic inner foveal layer thickness, ME: macular edema, MME: microcystic ME, CME: cystoid ME, EZ: ellipsoid zone, CBA: central bouquet abnormalities, SRF: presence of subretinal fluid
P-values refer to the statistical significance of the regression coefficient (B), which underlies the odds ratio for each category compared to the reference category. Reference categories are indicated by the absence of p-values and odds ratios. In case of variables with 3 categories the same category served as reference
*The odds ratio (OR) represents the change in odds of having a worse final BCVA for each one-unit increase in the baseline predictor
† For every less line (+0.1 logMAR) of baseline BCVA a patient was not more likely to gain >1 line in BCVA at 12 months after surgery, as the odds increase non significantly by 12%, holding all other variables constant